Co-amoxiclav-induced Stevens Johnson syndrome in a child

Area of Science:

• Pediatrics
• Dermatology
• Pharmacology

Background:

• Stevens-Johnson syndrome (SJS) is a rare, life-threatening mucocutaneous reaction, often drug-induced.
• Antibiotics, particularly sulfonamides, are frequently implicated in pediatric SJS cases.
• Co-amoxiclav is generally considered well-tolerated and has not been previously linked to SJS in children.

Observation:

• A case of SJS is presented in an 18-month-old child.
• The patient developed SJS following co-amoxiclav administration.
• Diagnosing SJS in children can be challenging, requiring exclusion of other conditions.

Findings:

• This case represents the first reported instance of co-amoxiclav as the sole causative agent for SJS in a pediatric patient.
• The immunologic pathogenesis of SJS remains incompletely understood.
• Co-amoxiclav-induced Stevens-Johnson syndrome in a young child is a significant finding.

Implications:

• Highlights the potential for co-amoxiclav to cause SJS, even if rare.
• Emphasizes the importance of considering SJS in children presenting with characteristic symptoms after antibiotic exposure.
• Underscores the need for prompt recognition, discontinuation of the offending drug, and supportive care for SJS management.